Misplaced Pages

Susoctocog alfa

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Medication

Pharmaceutical compound
Susoctocog alfa
Clinical data
Trade namesObizur
Other namesAntihemophilic factor (recombinant)
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B2
Drug classAntihemophilic factor
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
UNII
KEGG

Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.

Susoctocog alfa was approved for medical use in the United States in October 2014, and for medical use in the European Union in November 2015.

Factor VIII is one of the proteins needed for normal clotting of the blood.

References

  1. "Antihemophilic factor Use During Pregnancy". Drugs.com. 20 January 2020. Archived from the original on 16 July 2020. Retrieved 6 March 2020.
  2. "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
  3. "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Archived from the original on 20 February 2020. Retrieved 7 April 2024.
  4. "Obizur 500 U powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 13 April 2017. Retrieved 3 September 2020.
  5. ^ "Obizur (antihemophilic factor- recombinant, porcine sequence kit". DailyMed. 2 January 2020. Archived from the original on 24 July 2021. Retrieved 6 March 2020.
  6. ^ "Obizur EPAR". European Medicines Agency. 6 March 2020. Archived from the original on 11 August 2020. Retrieved 6 March 2020.
  7. Burness CB, Scott LJ (May 2016). "Susoctocog Alfa: A Review in Acquired Haemophilia A". Drugs. 76 (7): 815–21. doi:10.1007/s40265-016-0576-1. PMID 27098420. S2CID 10880049.
  8. "Obizur". U.S. Food and Drug Administration (FDA). 13 March 2018. Archived from the original on 23 April 2019. Retrieved 6 March 2020.
  9. "Obizur". U.S. Food and Drug Administration (FDA). 27 September 2019. STN: BL 125512. Archived from the original on 17 December 2019. Retrieved 6 March 2020.
Antihemorrhagics (B02)
Antihemorrhagics
(coagulation)
Systemic
Vitamin K
Coagulation
factors
Other
systemic
Local
Antifibrinolytics
Portal:


Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

Categories: